Multi-Model Platform for Cardiac Rhythm Gene Validation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current experimental platforms lack the capability to rapidly establish causal links between gene function and atrial fibrillation-associated phenotypes, limiting the validation of AF-associated genes due to electrophysiological differences and low throughput in existing models like mice and iPSC-derived cardiomyocytes.
Innovation Solution
A multi-model platform combining human iPSC-derived atrial-like cardiomyocytes with Drosophila heart models and computational simulations, enabling high-throughput characterization of action potential duration and rhythm parameters, and identifying Phospholamban (PLN) as a key regulator of cardiac rhythm through loss-of-function and gain-of-function studies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mice are used as a model to establish functional links between genes and rhythm phenotypes, then proteome homology with humans and ability to manipulate the genome are improved, but electrophysiological differences, relatively long lifespan and low throughput capacity limit the use
Solution Approach 1:
The research divides the gene validation process into multiple specialized model systems: mice for proteome homology studies, flies for high-throughput screening, and human iPSC-derived cardiomyocytes for human-specific phenotypes. Each model segment addresses specific research questions, allowing parallel validation pathways that collectively improve overall throughput while maintaining reliability.
Solution Approach 2:
The patent employs multiple model organisms (mice, flies, human iPSC-derived cardiomyocytes) that each serve multiple functions: mice provide proteome homology and genetic manipulability, flies offer high throughput and automated imaging, and human iPSC models provide human-specific electrophysiology. This multi-functional approach allows a single research platform to address diverse validation needs simultaneously.
2Productivity
If flies are used as a model for rapid evaluation of gene function on rhythm parameters, then short generation time and established automated kinetic imaging techniques are improved, but lack of atrial specificity limits the model
Solution Approach 1:
The patent uses human iPSC-derived cardiomyocytes as an intermediary model that bridges the high-throughput capability of fly models with human-specific atrial electrophysiology. The iPSC-derived cells serve as a mediator that allows rapid screening of gene function while maintaining human atrial specificity, thus resolving the contradiction between productivity and reliability.
3Reliability
If human iPSC-derived atrial-like cardiomyocytes are used to identify atrial-specific rhythm-regulating mechanisms, then atrial specificity is improved, but relative immaturity and inherent lack of tissue level integration limit translation to the adult human heart
Solution Approach 1:
The patent performs preliminary validation of gene function and phenotypic effects in high-throughput fly models and iPSC-derived cardiomyocyte models before translating findings to adult human heart studies. This preliminary action in simplified models accelerates the discovery process, allowing researchers to identify candidate genes and mechanisms rapidly before investing in more complex and time-consuming adult heart studies.
4Device complexity
If single model approaches are used to validate AF-associated genes, then simplicity of the approach is maintained, but ability to validate large cohorts of AF-associated genes is limited
Solution Approach 1:
The patent merges multiple model systems (mice, flies, human iPSC-derived cardiomyocytes) into an integrated validation platform. Each model complements the others by addressing their respective strengths: mice for proteome homology, flies for high throughput, and human iPSC models for human-specific phenotypes. This combination allows rapid validation of large cohorts of AF-associated genes while maintaining scientific rigor through multi-model verification.
Data Source
AI summary
The present disclosure provides for in-vitro generated cardiomyocytes, as well as methods of using such cardiomyocytes or variants thereof. The present disclosure also relates to methods of cell co-culture models of cardiac disorders, as well as methods of using such models or variants thereof.